CDA | Evidence Driven
CDA | Evidence Driven

bimekizumab

Details

Files
Generic Name:
bimekizumab
Project Status:
Complete
Therapeutic Area:
Ankylosing spondylitis
Manufacturer:
UCB Canada Inc.
Call for patient/clinician input open:
Brand Name:
Bimzelx
Project Line:
Reimbursement Review
Project Number:
SR0809-000
Call for patient/clinician input closed:
NOC Status at Filing:
Pre NOC
Performance Metric:
Achieved
Biosimilar:
No
Manufacturer Requested Reimbursement Criteria1:
The treatment of adult patients with active ankylosing spondylitis who have responded inadequately or are intolerant to conventional therapy.
Submission Type:
Initial
Fee Schedule:
Schedule A
Indications:
The treatment of adult patients with active ankylosing spondylitis who have responded inadequately or are intolerant to conventional therapy.
Recommendation Type:
Reimburse with clinical criteria and/or conditions
Final Recommendation:
  1. The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of Canada's Drug Agency. Reimbursement criteria from Canada's Drug Agency will be documented in the final recommendation, if applicable.
Key Milestones2
Call for patient/clinician input open30-Aug-23
Call for patient/clinician input closed24-Oct-23
Clarification:

- Patient input submission received from Arthritis Consumer Experts, Canadian Spondyloarthritis Association (CSA),Canadian Arthritis Patient Alliance (CAPA),Arthritis Society Canada (ASC) and Creaky Joints (CJ)

Submission received19-Oct-23
Submission accepted02-Nov-23
Review initiated03-Nov-23
Draft CADTH review report(s) provided to sponsor for comment30-Jan-24
Deadline for sponsors comments08-Feb-24
CADTH review report(s) and responses to comments provided to sponsor14-Mar-24
Expert committee meeting (initial)27-Mar-24
Draft recommendation issued to sponsor10-Apr-24
Draft recommendation posted for stakeholder feedback18-Apr-24
End of feedback period03-May-24
Final recommendation issued to sponsor and drug plans16-May-24
Final recommendation posted04-Jun-24
Deadline for sponsor to submit redaction requests on draft CADTH review report(s)31-May-24
CADTH review report(s) posted10-Oct-24

Files

Recommendation and Reasons View PDF
Clinical and Pharmacoeconomic Combined Report View PDF
Feedback on Draft Recommendation View PDF
Patient and Clinician Group input View PDF
Last Updated : October 10, 2024